Aarey Drugs & Pharmaceuticals Limited (BOM:524412)
India · Delayed Price · Currency is INR 68.82
+3.26 (4.97%)
At close: Jan 23, 2026
BOM:524412 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Operating Revenue | 4,283 | 4,739 | 3,956 | 4,190 | 4,928 | 3,484 | Upgrade |
Other Revenue | - | - | 69.65 | - | 1.73 | 30.12 | Upgrade |
| 4,283 | 4,739 | 4,026 | 4,190 | 4,929 | 3,514 | Upgrade | |
Revenue Growth (YoY) | -18.56% | 17.73% | -3.91% | -15.01% | 40.27% | 16.79% | Upgrade |
Cost of Revenue | 4,179 | 4,621 | 3,819 | 4,039 | 4,721 | 3,378 | Upgrade |
Gross Profit | 103.16 | 118.23 | 206.4 | 150.87 | 208.51 | 136.38 | Upgrade |
Selling, General & Admin | 8.55 | 16.74 | 14.21 | 15.54 | 20.46 | 3.96 | Upgrade |
Other Operating Expenses | 29.6 | 30.9 | 77.5 | 52.67 | 67.9 | 40.91 | Upgrade |
Operating Expenses | 59.84 | 67.09 | 108.69 | 83.95 | 108.24 | 54.07 | Upgrade |
Operating Income | 43.32 | 51.15 | 97.71 | 66.92 | 100.27 | 82.31 | Upgrade |
Interest Expense | -33.76 | -35.42 | -41.95 | -25.4 | -18.13 | -23.18 | Upgrade |
Interest & Investment Income | 56.04 | 56.04 | - | 26.33 | 20.09 | 24.29 | Upgrade |
Currency Exchange Gain (Loss) | 0.48 | 0.48 | -0.52 | -4.49 | 0.39 | 0.04 | Upgrade |
Other Non Operating Income (Expenses) | -3.73 | -11.23 | -1.8 | -3.26 | -2.24 | -0.44 | Upgrade |
Pretax Income | 62.35 | 61.02 | 53.43 | 60.1 | 100.37 | 83.01 | Upgrade |
Income Tax Expense | 26.52 | 20.78 | 6.59 | 22.39 | 34.82 | 17.87 | Upgrade |
Net Income | 35.83 | 40.24 | 46.84 | 37.71 | 65.55 | 65.14 | Upgrade |
Net Income to Common | 35.83 | 40.24 | 46.84 | 37.71 | 65.55 | 65.14 | Upgrade |
Net Income Growth | -40.38% | -14.09% | 24.20% | -42.47% | 0.62% | 12.44% | Upgrade |
Shares Outstanding (Basic) | 28 | 28 | 25 | 25 | 24 | 23 | Upgrade |
Shares Outstanding (Diluted) | 28 | 28 | 25 | 25 | 24 | 23 | Upgrade |
Shares Change (YoY) | 6.38% | 11.18% | -0.26% | 5.84% | 2.95% | - | Upgrade |
EPS (Basic) | 1.26 | 1.42 | 1.84 | 1.48 | 2.72 | 2.79 | Upgrade |
EPS (Diluted) | 1.25 | 1.42 | 1.84 | 1.48 | 2.72 | 2.79 | Upgrade |
EPS Growth | -44.18% | -22.83% | 24.32% | -45.59% | -2.36% | 12.44% | Upgrade |
Free Cash Flow | 30.61 | 50.96 | -37.16 | -23.25 | -17.03 | 25.98 | Upgrade |
Free Cash Flow Per Share | 1.08 | 1.80 | -1.46 | -0.91 | -0.71 | 1.11 | Upgrade |
Gross Margin | 2.41% | 2.50% | 5.13% | 3.60% | 4.23% | 3.88% | Upgrade |
Operating Margin | 1.01% | 1.08% | 2.43% | 1.60% | 2.03% | 2.34% | Upgrade |
Profit Margin | 0.84% | 0.85% | 1.16% | 0.90% | 1.33% | 1.85% | Upgrade |
Free Cash Flow Margin | 0.71% | 1.07% | -0.92% | -0.56% | -0.34% | 0.74% | Upgrade |
EBITDA | 65.02 | 70.6 | 114.69 | 82.66 | 120.15 | 91.51 | Upgrade |
EBITDA Margin | 1.52% | 1.49% | 2.85% | 1.97% | 2.44% | 2.60% | Upgrade |
D&A For EBITDA | 21.69 | 19.45 | 16.98 | 15.74 | 19.88 | 9.2 | Upgrade |
EBIT | 43.32 | 51.15 | 97.71 | 66.92 | 100.27 | 82.31 | Upgrade |
EBIT Margin | 1.01% | 1.08% | 2.43% | 1.60% | 2.03% | 2.34% | Upgrade |
Effective Tax Rate | 42.53% | 34.05% | 12.34% | 37.25% | 34.69% | 21.53% | Upgrade |
Revenue as Reported | 4,388 | 4,838 | 4,026 | 4,217 | 4,954 | 3,554 | Upgrade |
Advertising Expenses | - | 3.36 | 1.71 | 2.56 | 3.89 | 1.59 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.